Opentrons vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Opentrons democratizes lab automation with 10,000+ OT-2 and Flex robotic systems deployed globally; raised $200M+ including $20M Series C in Nov 2025; partnered with BD and HighRes for AI agent-to-agent workflows.
About
Opentrons Labworks is a New York-based life sciences company that designs and manufactures affordable, open-source liquid-handling robots for research laboratories. Founded in 2014, Opentrons'' mission is to democratize biology by making advanced lab automation accessible to life scientists at any institution — from academic labs with limited budgets to leading pharmaceutical companies. Its flagship products, the OT-2 and the newer Opentrons Flex, are programmable robotic platforms that automate repetitive liquid-handling tasks such as PCR setup, nucleic acid extraction, ELISA assays, and next-generation sequencing sample preparation.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Opentrons vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.